Safety and status report of SARS-CoV-2 vaccination in patients with Wilson's disease.
Abstract Objective To examine the risk of exacerbation after vaccination against SARS-CoV-2 in patients with Wilson's disease. Methods Collect the participants' characteristics and the current status of SARS-CoV-2 vaccination. To compare the vaccination rates of Wilson's disease patients in different regions of China. To analyze the subjective reasons of patients who are not vaccinated. Differences in Unified Wilson's Disease Rating Scale (UWDRS) scores between vaccinated and unvaccinated patients were analyzed using independent samples t-tests. Paired samples t-tests were used to analyze whether there were differences in UWDRS scores before and after vaccination in vaccinated patients. The risk of increased UWDRS scores was evaluated using logistic regression. Results Among the 554 patients with Wilson's disease included in the study, the mean age was 25 years. 368 (66.4%) received at least one dose of the SARS-CoV-2 vaccine. 186 (33.6%) were not vaccinated. Patients with Wilson's disease chose not to receive the vaccine mainly because of the advice of the medical center (n = 83,44.6%), fear of worsening Wilson's disease symptoms (n = 63, 33.9%), and doubts about the effectiveness and safety of the vaccine (n = 40, 21.5%). There were no significant differences in UWDRS scores between vaccinated and unvaccinated patients (P > 0.05). There were also no differences in UWDRS scores before and after vaccination (P > 0.05). Vaccination against SARS-CoV-2 was not significantly associated with increased scores of UWDRS (OR = 0.924, 95% CI: 0.336–2.540, P = 0.879), hepatic subscale (OR = 0.170, 95% CI: 0.148–3.027, P = 0.603), neurological subscale (OR = 1.322, 95% CI: 0.219–7.984, P = 0.761), and psychiatric subscale (OR = 1.011, 95% CI: 0.183–5.571, P = 0.990). Conclusion SARS-CoV-2 vaccination was not significantly associated with aggravated liver, neurological, or mental damage in patients, which provides a basis for the safety of SARS-CoV-2 vaccination. It also provides a reference for patients with other heavy metal metabolism disorders, nervous system damage, and other similar diseases to be vaccinated against SARS-CoV-2..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
ResearchSquare.com - (2023) vom: 29. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Han, Hui [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.21203/rs.3.rs-2152063/v1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XRA037647660 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XRA037647660 | ||
| 003 | DE-627 | ||
| 005 | 20231130131146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221022s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21203/rs.3.rs-2152063/v1 |2 doi | |
| 035 | |a (DE-627)XRA037647660 | ||
| 035 | |a (ResearchSquare)10.21203/rs.3.rs-2152063/v1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Han, Hui |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety and status report of SARS-CoV-2 vaccination in patients with Wilson's disease. |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Objective To examine the risk of exacerbation after vaccination against SARS-CoV-2 in patients with Wilson's disease. Methods Collect the participants' characteristics and the current status of SARS-CoV-2 vaccination. To compare the vaccination rates of Wilson's disease patients in different regions of China. To analyze the subjective reasons of patients who are not vaccinated. Differences in Unified Wilson's Disease Rating Scale (UWDRS) scores between vaccinated and unvaccinated patients were analyzed using independent samples t-tests. Paired samples t-tests were used to analyze whether there were differences in UWDRS scores before and after vaccination in vaccinated patients. The risk of increased UWDRS scores was evaluated using logistic regression. Results Among the 554 patients with Wilson's disease included in the study, the mean age was 25 years. 368 (66.4%) received at least one dose of the SARS-CoV-2 vaccine. 186 (33.6%) were not vaccinated. Patients with Wilson's disease chose not to receive the vaccine mainly because of the advice of the medical center (n = 83,44.6%), fear of worsening Wilson's disease symptoms (n = 63, 33.9%), and doubts about the effectiveness and safety of the vaccine (n = 40, 21.5%). There were no significant differences in UWDRS scores between vaccinated and unvaccinated patients (P > 0.05). There were also no differences in UWDRS scores before and after vaccination (P > 0.05). Vaccination against SARS-CoV-2 was not significantly associated with increased scores of UWDRS (OR = 0.924, 95% CI: 0.336–2.540, P = 0.879), hepatic subscale (OR = 0.170, 95% CI: 0.148–3.027, P = 0.603), neurological subscale (OR = 1.322, 95% CI: 0.219–7.984, P = 0.761), and psychiatric subscale (OR = 1.011, 95% CI: 0.183–5.571, P = 0.990). Conclusion SARS-CoV-2 vaccination was not significantly associated with aggravated liver, neurological, or mental damage in patients, which provides a basis for the safety of SARS-CoV-2 vaccination. It also provides a reference for patients with other heavy metal metabolism disorders, nervous system damage, and other similar diseases to be vaccinated against SARS-CoV-2. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Zhao, Dan |4 aut | |
| 700 | 1 | |a Fang, Xinru |4 aut | |
| 700 | 1 | |a Yang, Wenming |4 aut | |
| 700 | 1 | |a Wang, Mengli |4 aut | |
| 700 | 1 | |a Liu, Qianzhuo |4 aut | |
| 700 | 1 | |a Wang, Luyao |4 aut | |
| 700 | 1 | |a Ji, Zhihui |4 aut | |
| 700 | 1 | |a Zhang, Juan |4 aut | |
| 700 | 1 | |a Hou, Zhifeng |4 aut | |
| 700 | 1 | |a Hua, Lei |4 aut | |
| 700 | 1 | |a Wang, Yu |4 aut | |
| 700 | 1 | |a Wu, Limin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ResearchSquare.com |g (2023) vom: 29. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:29 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21203/rs.3.rs-2152063/v1 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XRA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 29 |c 11 | ||